Fig. 5: Use of the MTBP in Cancer Core Europe.
a, Patients of the CCE cohort recommended for one of the Basket of Baskets trial arms available at the moment of the molecular tumor board discussion. The pie chart shows the proportion of these patients that were not enrolled due to clinical deterioration and/or screening failures. For the remaining cases, other investigational treatments were evaluated in the respective patient’s medical institution without requiring CCE consensus (data not shown). b, Patients in which the MTBP issued an alert due to germline variant(s) associated with inherited cancer risk (restricted to the 375 patients with sequencing of both tumor and normal-paired samples). The pie chart shows the proportion of these cases that would have been overlooked by current germline testing guidelines, as variant carriers did not meet personal criteria. Bar plots detail the genes in which these pathogenic variants were identified and whether they are currently described as increasing the risk for the respective patient’s index cancer type. c, The MTBP reports used in CCE contain an integrated dashboard with clinical and pathology information, details of the sequencing assay(s) and a version control of the resources used to annotate the data. Clinically relevant molecular signatures are listed together with individual gene alterations, the latter organized in three different tables according to their functional classification (functionally relevant, unclassified and functionally neutral). These tables summarize the evidence supporting the variants’ functional classification and their associated actionability, including in-house clinical initiatives (prioritizing eligibility for clinical trials available across the CCE network) and matching with cancer biomarkers reported to date (diagnosis, prognosis and drug response, tiered according to the ESMO-ESCAT scale; see Fig. 4). Access to detailed information is provided by the use of interactive elements in the HTML report, as exemplified here by the pop-up windows opened in 1–4. d, The lines represent the time (median and IQR) devoted to discussing each patient’s case during the CCE virtual molecular tumor board meetings. The circles indicate the accumulated number of reviewed cases (overall 500 patients). BoB, Basket of Baskets; VAF, variant allele frequency.
